European Journal of Molecular & Clinical Medicine

Abstract

Rheumatoid arthritis is a chronic inflammatory illness that affects many elderly people's quality of life. Combinational DMARDs are a new therapeutic approach in managing disease conditions, based on the concept that the two medications work in two distinct routes to diminish (or) delay disease development.This study aimed to develop and improve the pharmacokinetic and safety margin of SLN as an MTX carrier in vitro. As a result, an attempt was made to construct SLN for the delivery of MTX and DOX and to evaluate size, stability, and drug release characteristics.Methods: supplied the methotrexate (Chennai, India). Micro Labs Pvt. Ltd provided the Doxycycline (Hosur, India). Tokyo Chemicals Industries provided the tristearin. Himedia Laboratories Pvt. Ltd provided stearic acid, Pluronic F68, Dialysis Membrane, and Membrane Filter (Mumbai, India).
SD fine chem. Lyophilization eliminates excess water from SLN and improves its storage stability. A calibration curve for the medicines MTX/DOX was created using standard solutions of MTX and DOX, each with final concentrations of 10, 20, 30, 40, and 50 g/mL. An experiment using a simple and sensitive spectrophotometric approach was used to determine the number of pharmaceuticals present in the SLN formulation.Both MTX and DOX were discovered to have higuchi first-order kinetics and Higuchi zero-order kinetics, respectively. The release was initially relatively low (up to 3 hours) since it takes time for the medications to diffuse out of the lipid matrix, suggesting a strong embodiment of pharmaceuticals in the lipid matrix and surrounding poloxamer coating & thickness (dependent on concentration). The release has become concentration-dependent as the MTX loaded in the SLN has decreased.Preliminary data show that the designed SLNs can administer dual medicines MTX and DOX without incompatibility. However, in vivo studies relevant to RA are required to validate their efficacy in vivo